Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with limited diagnostic and therapeutic advancements, underscoring the urgent need for novel biomarkers and targeted therapies.
Methyltransferase-like 3 (METTL3), a pivotal regulator of N
